RSS | Login | Register

VALSTAR

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare VALSTAR to:

Generic Name for VALSTAR

Valrubicin 40mg/mL; soln for intravesical instillation after dilution; contains 50% polyoxyl castor oil/50% dehydrated alcohol; preservative-free.

Legal Classification:

Pharmacological Class for VALSTAR

Anthracycline.

Manufacturer of VALSTAR

Endo Pharmaceuticals

Indications for VALSTAR

Intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.

Adult dose for VALSTAR

Drain bladder before instilliation. 800mg given intravesically via urethral catheter once weekly for 6 weeks. Retain drug for 2 hours before voiding, then void.

Children's dosing for VALSTAR

Not recommended.

Contraindications for VALSTAR

Concurrent UTI. Small bladder capacity (eg, unable to tolerate a 75mL instillation).

Precautions for VALSTAR

Monitor for disease recurrence or progression with cystoscopy, biopsy, and urine cytology every 3 months; if there is not a complete response of CIS to treatment after 3 months or if CIS recurs, cystectomy must be reconsidered. Severe irritable bladder symptoms. Perforated bladder. Bladder mucosa compromised. Delay administration for at least 2 weeks after transurethral resection and/or fulguration. Maintain adequate hydration. Pregnancy (Cat. C); avoid, both males and females should use effective birth control. Nursing mothers: not recommended.

Adverse Reactions for VALSTAR

Bladder symptoms (eg, urinary frequency, dysuria, urinary urgency, spasm, hematuria, pain, incontinence, cystitis, nocturia, local burning, urethral pain, pelvic pain, UTI).

How is VALSTAR supplied?

Single-use vials—4, 24

Related Disease:

Cancer, bladder

FDA cancer drug approval rate reviewed in JNCI

February 19, 2010

The FDA's Office of Oncology Drug Products approved 53 new indications for the use of oncology and hematology drugs and biologics from July 2005 to the end of 2007.

Phase 3 study of perifosine for metastatic colon cancer

February 03, 2010

Æterna Zentaris and Keryx Biopharmaceuticals announced agreement with the FDA regarding a Special Protocol Assessment on its Phase 3 trial for perifosine (KRX-0401) for the treatment of refractory metastatic colorectal cancer.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of ADXS11-001 for advanced cervical cancer

December 15, 2009

Advaxis announced that it will collaborate with the Gynecologic Oncology Group (GOG) in a Phase 2, multicenter clinical trial of ADXS11-011 for the treatment of advanced cervical cancer in women who have failed prior cytotoxic therapy.